What ChondroFiller is designed to treat

ChondroFiller™ exists to repair damaged hip cartilage without surgery — specifically for patients who have lost cartilage down to the bone or near to it in a defined area of the joint. Delivered as a single outpatient injection under ultrasound guidance, it places an acellular scaffold of murine-derived Type I collagen directly into the affected hip joint. Once in place, the gel sets within minutes and acts as a structural matrix, recruiting the patient's own progenitor cells from the surrounding synovium and subchondral bone to migrate in and initiate repair — a process called acellular matrix-induced chondrogenesis. This is the mechanism on which everything else in this article depends.

The formal CE-mark indication is Outerbridge grade III or IV cartilage damage — partial-to-full-thickness loss — in lesions up to 6 cm² within a mechanically stable hip joint. Younger and middle-aged active patients with focal cartilage lesions, often secondary to femoroacetabular impingement (FAI), represent a typical candidate group. Post-market surveillance across more than 19,000 cases since 2013 records a complaint rate of approximately 0.06% and zero serious adverse device effects — a safety profile that holds only when patient selection is right.

Hip osteoarthritis that is too advanced — or too mild

The indication sits within a defined band of cartilage damage. Too little and the scaffold has nothing meaningful to fill; too much and the joint has deteriorated beyond the point where focal repair can help.

At the upper end, advanced hip osteoarthritis removes a patient from the indicated range. Clinicians use Tönnis grading and Kellgren–Lawrence classification to describe OA severity on imaging; Tönnis grade 2 or above, or Kellgren–Lawrence grade IV, generally indicates moderate-to-severe joint space narrowing and diffuse structural change across the hip rather than a contained focal defect. A collagen scaffold placed into a joint in this state cannot compensate for global architectural loss. UK clinical pathways may apply local thresholds, and the precise cut-off used at assessment can vary, so individual clinical review — rather than self-assigned grading — is always the appropriate starting point.

At the lower end, surface-only roughening classified as Outerbridge grade I, or early grade II, does not meet the published CE-mark criteria. These lesions are too superficial to provide the scaffold with a viable defect bed into which progenitor cells can migrate.

Defect size imposes a third boundary: lesions larger than approximately 6 cm² exceed the scaffold's reliable bridging capacity in the injectable form, and patients with diffuse global cartilage loss across the hip face the same limitation for the same reason. This upper size threshold is specific to the injectable pathway; the arthroscopic Liquid Cartilage™ surgical procedure has its own containment and border-integrity criteria, and the two should not be conflated when comparing options.

Systemic and medical conditions that rule out the injection

Several medical conditions make ChondroFiller™ unsuitable regardless of how the hip looks on imaging, because the risk lies not in the joint itself but in the patient's systemic health.

Allergy to murine-derived collagen. Because the scaffold is composed of Type I collagen sourced from mice, a known allergy to murine proteins or animal-derived collagen is a direct absolute contraindication. There is no reformulated alternative.

Active joint or systemic infection. Introducing any implant into an infected hip risks accelerating that infection and causing scaffold failure. Active or suspected septic arthritis — or a concurrent systemic infection — excludes any intra-articular procedure until infection has fully resolved.

Systemic inflammatory arthritis. In rheumatoid or psoriatic arthritis affecting the hip, the synovial environment remains persistently inflamed. That inflammation can degrade the collagen scaffold before the patient's own progenitor cells have had sufficient time to migrate in and begin tissue repair, undermining the mechanism the treatment depends on.

Immunosuppression and active malignancy. ChondroFiller is an acellular scaffold — it contains no cells of its own and relies entirely on the patient's own progenitor cells migrating into the matrix. Immunosuppressive therapy and active malignancy impair that biological response, making meaningful cell ingrowth unlikely.

Uncontrolled bleeding disorders. Any intra-articular injection carries a risk of haemarthrosis; in patients with an uncontrolled bleeding disorder, that risk becomes procedurally prohibitive.

Pregnancy and breastfeeding. As a precautionary measure consistent with standard intra-articular injection practice, ChondroFiller is not indicated during pregnancy or whilst breastfeeding.

Mechanical problems that must be resolved before considering the injection

Not every patient who is currently unsuitable is permanently excluded. A distinct group of patients are unsuitable now because a prior mechanical step is missing — once that step is taken, ChondroFiller™ may become entirely appropriate.

The clearest example is femoroacetabular impingement. Cam-type FAI is a recognised cause of anterosuperior acetabular cartilage lesions in younger active patients: the abnormal bony contour of the femoral head repeatedly contacts the acetabular rim, shearing the cartilage surface over time. Placing a collagen scaffold on that surface without first correcting the impingement addresses the damage whilst leaving the mechanism that caused it intact. In this situation, the scaffold cannot reasonably be expected to survive.

The same sequencing logic applies to significant hip malalignment and to major labral tears that compromise joint stability. Abnormal loading concentrates mechanical stress on the repair site; the scaffold's effectiveness depends on the joint being able to provide the relatively protected environment that cell ingrowth requires. Surgery to address FAI or stabilise the joint is a separate prior step — not a component of the ChondroFiller injection itself.

Once the mechanical cause has been treated and the joint environment is confirmed as structurally sound, ChondroFiller may be reconsidered on its own merits. These are sequencing contraindications, and the distinction matters: a patient turned away today is not necessarily being told the door is permanently closed.

Timing factors and practical considerations

Suitability is not only about the state of the hip — three practical circumstances can make the timing or context of the injection inappropriate even when the cartilage damage itself fits the indication.

Proximity to planned hip replacement. For patients expecting to proceed to total hip replacement within approximately six months, an intra-articular injection at this stage carries a meaningful clinical risk: evidence associates injection within six to seven months of arthroplasty with an elevated rate of periprosthetic joint infection. The appropriate course in this situation is to defer the injection or to reconsider the overall treatment sequence with the treating clinician before proceeding.

Ultrasound access to the hip joint. Because the scaffold gels irreversibly within minutes of placement — as noted earlier — accurate image-guided delivery is essential and not an optional refinement. In rare cases, such as extreme body habitus or implanted hardware obstructing the access window, reliable ultrasound visualisation of the joint may not be achievable, and the injection approach would not be appropriate for that patient.

Expectation and recovery adherence. ChondroFiller's mechanism depends on the patient's own progenitor cells migrating into the scaffold matrix over weeks to months; there is no immediate analgesic effect to bridge that period. Part of a thorough suitability assessment is ensuring the patient understands this biological timeline and is willing and able to follow post-injection activity guidance during scaffold integration. Ensuring that understanding rests with the clinician — it is a step in preparation, not a judgement of the patient.

How Lincolnshire Hip assesses candidacy

The four lenses Lincolnshire Hip uses to evaluate candidacy — physics, chemistry, biology, and timing — make explicit what the preceding sections show in detail: unsuitability is rarely decided by a single factor in isolation.

Physics asks whether joint mechanics and alignment are sound enough to protect a placed scaffold. Chemistry considers whether the inflammatory and metabolic environment will permit cell ingrowth rather than degrade it. Biology assesses the patient's regenerative potential — the capacity of host progenitor cells to populate the matrix. Timing asks whether any adjacent circumstance, from planned arthroplasty to unresolved structural pathology, changes the risk–benefit calculation.

This framework also clarifies which exclusions are permanent and which are not. A documented collagen allergy does not change; end-stage diffuse joint destruction cannot be reversed by this intervention. But a patient excluded on physics or timing grounds — unaddressed FAI, proximity to hip replacement — may become entirely suitable once that prior step is taken. The assessment does not simply sort patients into two columns; it identifies what, if anything, would need to change.

Lincolnshire Hip's candidacy assessment draws on clinical history, imaging review, and where appropriate an ultrasound evaluation of the hip joint. It is consultant-led rather than protocol-driven, and the group accepts patients without a GP referral at clinics in Sleaford and Grantham.